Q4 2021 13F Holders as of 31 Dec 2021
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,963,102
-
Number of holders
-
224
-
Total 13F shares, excl. options
-
67,646,883
-
Shares change
-
+975,395
-
Total reported value, excl. options
-
$5,688,385,130
-
Value change
-
+$80,515,709
-
Put/Call ratio
-
916%
-
Number of buys
-
117
-
Number of sells
-
-88
-
Price
-
$84.09
Significant Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q4 2021
253 filings reported holding RARE - Ultragenyx Pharmaceutical Inc. - COMMON STOCK as of Q4 2021.
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) has 224 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 67,646,883 shares
of 95,963,102 outstanding shares and own 70.49% of the company stock.
Largest 10 shareholders include PRICE T ROWE ASSOCIATES INC /MD/ (11,525,089 shares), VANGUARD GROUP INC (5,920,568 shares), Capital International Investors (5,369,774 shares), FEDERATED HERMES, INC. (3,986,870 shares), BlackRock Inc. (3,484,652 shares), WELLINGTON MANAGEMENT GROUP LLP (2,877,403 shares), Clearbridge Investments, LLC (2,778,859 shares), Capital World Investors (2,766,844 shares), ALKEON CAPITAL MANAGEMENT LLC (2,308,130 shares), and STATE STREET CORP (1,678,841 shares).
This table shows the top 224 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.